Bulletin of Russian State Medical University,
Journal Year:
2024,
Volume and Issue:
2024(3)
Published: June 1, 2024
Systemic
lupus
erythematosus
(SLE)
is
a
chronic
autoimmune
disease
characterized
by
inflammation
of
connective
tissue
and
damage
to
various
organs,
including
joints,
skin,
kidneys
heart.
The
has
significant
gender
predisposition
more
common
in
women.
pathogenesis
SLE
based
on
violation
immunological
tolerance,
accompanied
activation
B
lymphocytes
the
production
autoantibodies.
Recent
advances
basic
research
have
significantly
deepened
understanding
immunopathogenetic
mechanisms
SLE,
which
justifies
use
new
pharmacotherapeutic
approaches.
These
approaches
involve
biological
drugs
aimed
at
blocking
activity
type
I
interferon
(IFN)
or
its
receptors.
article
discusses
molecular
response
modern
methods
for
diagnosing
signature,
treatment
pathway.
possible
role
signature
stratification
patients
also
discussed.
Such
will
make
it
effective
select
regimens
taking
into
account
individual
characteristics
immune
each
patient.
This
may
increase
effectiveness
treatment,
reduce
likelihood
side
effects
improve
prognosis
with
SLE.
Exploration of Immunology,
Journal Year:
2024,
Volume and Issue:
unknown, P. 640 - 657
Published: Oct. 21, 2024
The
impaired
function
of
regulatory
T
(Treg)
cells
and
the
imbalance
Treg/Th17
play
a
central
role
in
developing
autoimmune
diseases
such
as
systemic
lupus
erythematosus
(SLE).
Treg
are
crucial
for
maintaining
immune
homeostasis
tolerance
to
self-antigens.
One
most
important
transcription
factors
that
regulate
differentiation
is
FOXP3
protein.
Aberrant
epigenetic
modifications
affecting
gene
expression
consequently
dysregulated
have
been
implicated
pathogenesis
SLE.
Therefore,
understanding
intricate
interplay
between
pattern
mechanisms
(e.g.,
DNA
methylation,
histone
non-coding
RNAs
microRNAs
long
RNAs)
unravelling
underlying
Moreover,
targeting
these
pathways
may
offer
novel
therapeutic
strategies
restoring
balance
ameliorating
pathology.
This
review
report
aimed
provide
an
update
on
controlling
SLE
disease.
Frontiers in Immunology,
Journal Year:
2024,
Volume and Issue:
15
Published: Dec. 4, 2024
Autoimmune
diseases,
characterized
by
the
immune
system's
attack
on
body's
own
tissues,
affect
millions
of
people
worldwide.
Current
treatments,
which
primarily
rely
broad
immunosuppression
and
symptom
management,
are
often
associated
with
significant
adverse
effects
necessitate
lifelong
therapy.
This
review
explores
next
generation
therapies
for
immune-mediated
including
chimeric
antigen
receptor
(CAR)
T
cell
regulatory
(Treg)-based
approaches,
offer
prospect
targeted,
durable
disease
remission.
Notably,
we
highlight
emergence
CD19-targeted
CAR
therapies,
their
ability
to
drive
sustained
remission
in
B
cell-mediated
autoimmune
suggesting
a
possible
paradigm
shift.
Further,
discuss
therapeutic
potential
Type
1
FOXP3
Bulletin of Russian State Medical University,
Journal Year:
2024,
Volume and Issue:
2024(3)
Published: June 1, 2024
Systemic
lupus
erythematosus
(SLE)
is
a
chronic
autoimmune
disease
characterized
by
inflammation
of
connective
tissue
and
damage
to
various
organs,
including
joints,
skin,
kidneys
heart.
The
has
significant
gender
predisposition
more
common
in
women.
pathogenesis
SLE
based
on
violation
immunological
tolerance,
accompanied
activation
B
lymphocytes
the
production
autoantibodies.
Recent
advances
basic
research
have
significantly
deepened
understanding
immunopathogenetic
mechanisms
SLE,
which
justifies
use
new
pharmacotherapeutic
approaches.
These
approaches
involve
biological
drugs
aimed
at
blocking
activity
type
I
interferon
(IFN)
or
its
receptors.
article
discusses
molecular
response
modern
methods
for
diagnosing
signature,
treatment
pathway.
possible
role
signature
stratification
patients
also
discussed.
Such
will
make
it
effective
select
regimens
taking
into
account
individual
characteristics
immune
each
patient.
This
may
increase
effectiveness
treatment,
reduce
likelihood
side
effects
improve
prognosis
with
SLE.
